Prognostic role of early prostate specific antigen changes after [ 177 Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: A meta-analysis.

Luca M Giovanella Maria Luisa GaroMarco CuzzocreaGaetano PaoneKen Herrmann

Published in: European journal of clinical investigation (2023)

Lu]Lu-PSMA cycles, with a significantly longer OS compared to stable or increased PSA levels, respectively. Accordingly, any PSA decline after 1-2 cycles of therapy should be regarded as a favourable prognostic factor for OS.

Keyphrases

prostate cancer
prognostic factors
radical prostatectomy
pet ct
pet imaging
stem cells
computed tomography
bone marrow
smoking cessation
replacement therapy